Skip to main content

Nivolumab Disease Interactions

There are 5 disease interactions with nivolumab.

Moderate

Nivolumab (applies to nivolumab) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

There are no data available on the use of nivolumab-containing products in patients with severe hepatic impairment or autoimmune liver disease. No dose adjustment is recommended for patients with mild or moderate hepatic impairment during use of IV nivolumab; data not available for subcutaneous nivolumab. Monitor liver enzymes at baseline and periodically during therapy. Therapy with nivolumab-containing products may cause immune-mediated hepatitis and/or hepatotoxicity.

Moderate

Nivolumab (applies to nivolumab) pneumonitis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pleuropulmonary Infection, History - Radiation Therapy

Use of nivolumab-containing products can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation.

Moderate

PD-1/PD-L1 inhibitors (applies to nivolumab) HSCT

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Transplantation

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. It is recommended to follow patients closely for evidence of transplant-related complications and intervene promptly. The benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody before or after an allogeneic HSCT should be considered.

Moderate

PD-1/PD-L1 inhibitors (applies to nivolumab) myasthenia gravis

Moderate Potential Hazard, Moderate plausibility.

Myasthenic syndrome/myasthenia gravis (including exacerbation) has been reported with the use of programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies. Care should be exercised when using PD-1/PD-L1 blocking antibodies in patients with myasthenia gravis.

Moderate

PD-1/PD-L1 inhibitors (applies to nivolumab) organ transplant

Moderate Potential Hazard, Moderate plausibility.

Solid organ transplant rejection and other transplant (including corneal graft) rejection have been reported with the use of programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies. Care should be exercised when using PD-1/PD-L1 blocking antibodies in patients who have received a solid organ or other transplant.

Switch to professional interaction data

Nivolumab drug interactions

There are 588 drug interactions with nivolumab.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer